Prof Linda Mileshkin
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
541 Scholarly works
21 Projects
HIGHLIGHTS
2026
Journal article
No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma
DOI: 10.1016/j.ejca.2026.1168852026
Journal article
FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.
DOI: 10.1200/jco.2026.44.16_suppl.30722026
Research grants (ARC, NHMRC, MRFF)
Super-Next: Complete Genome Profiling for Cancer of Unknown Primary
2020
Research grants (ARC, NHMRC, MRFF)
Super-Next: Complete Genome Profiling for Cancer of Unknown Primary
2020
Research grants (ARC, NHMRC, MRFF)
Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a Novel Radiopharmaceutical Targeting Cancer-Associated Fibroblasts for the Diagnosis and Treatment of Patients With Cancer of Unknown Primary: The FAPI-CUP Trial
2015
Journal article
Whole-genome characterization of chemoresistant ovarian cancer
DOI: 10.1038/nature144102013
Journal article
Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary
DOI: 10.1002/path.4251
RECENT SCHOLARLY WORKS
2026
Journal article
IGNITE-Cerala: A phase II signal-seeking trial of ceralasertib targeting recurrent high-grade serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
DOI: 10.1200/jco.2026.44.16_suppl.55872026
Journal article
Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study.
DOI: 10.1200/jco.2026.44.16_suppl.55152026
Journal article
Safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients with biliary tract cancer (BTC): A first-in-human phase 1/2a study (BLUESTAR).
DOI: 10.1200/jco.2026.44.16_suppl.41062026
Journal article
Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).
DOI: 10.1200/jco.2026.44.16_suppl.55032026
Journal article
Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations
DOI: 10.1016/j.modpat.2026.1010002026
Journal article
First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion.
DOI: 10.1200/jco.2026.44.16_suppl.30132026
Journal article
Final overall survival (OS) results from the phase 3 ROSELLA trial: Relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (PROC) (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223)
DOI: 10.1016/j.ygyno.2026.02.0222026
Journal article
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial
DOI: 10.1016/j.ijgc.2026.104556